Improved Noninvasive prediction of Liver Fibrosis by Liver Stiffness Measurement in Patients with Nonalcoholic Fatty Liver Disease Accounting for Controlled Attenuation Parameter Values

doi:10.1002/HEP.28843

Home
/
Papers
/
Improved Noninvasive prediction of Liver Fibrosis by Liver Stiffness Measurement in Patients with Nonalcoholic Fatty Liver Disease Accounting for Controlled Attenuation Parameter Values

Journal Article•DOI•

Improved Noninvasive prediction of Liver Fibrosis by Liver Stiffness Measurement in Patients with Nonalcoholic Fatty Liver Disease Accounting for Controlled Attenuation Parameter Values

Salvatore Petta¹, Vincent Wai-Sun Wong², Calogero Cammà¹, Jean-Baptiste Hiriart, Grace Lai-Hung Wong², Fabio Marra³, Julien Vergniol, Anthony W.H. Chan², Vito Di Marco¹, Wassil Merrouche, Henry Lik-Yuen Chan², Marco Barbara¹, Brigitte Le-Bail⁴, Umberto Arena³, Antonio Craxì¹, Victor de Ledinghen - Show less +12 more•Institutions (4)

University of Palermo¹, The Chinese University of Hong Kong², University of Florence³, French Institute of Health and Medical Research⁴

01 Apr 2017-Hepatology (Hepatology)-Vol. 65, Iss: 4, pp 1145-1155

TL;DR: In patients with NAFLD, CAP values should always be taken into account in order to avoid overestimations of liver fibrosis assessed by transient elastography.

read less

About: This article is published in Hepatology.The article was published on 2017-04-01 and is currently open access. It has received 168 citations till now. The article focuses on the topics: Nonalcoholic fatty liver disease.

...read moreread less

Citations

PDF

Open Access

More filters

Journal Article•DOI•

Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease.

[...]

Laurent Castera¹, Mireen Friedrich-Rust², Rohit Loomba³•Institutions (3)

French Institute of Health and Medical Research¹, Goethe University Frankfurt², University of California, San Diego³

01 Apr 2019-Gastroenterology

TL;DR: The current state of the noninvasive assessment of liver disease in NAFLD is summarized, and an expert synthesis of how these nonin invasive tools could be utilized in clinical practice is provided.

...read moreread less

780 citations

Journal Article•DOI•

Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease

[...]

Peter J Eddowes, Magali Sasso, Michael Allison, Emmanouil Tsochatzis¹, Quentin M. Anstee², David Sheridan³, Indra Neil Guha⁴, Jeremy F. L. Cobbold⁵, Jonathan J Deeks⁶, Valérie Paradis⁷, Pierre Bedossa⁷, Philip N. Newsome⁶, Philip N. Newsome⁸ - Show less +9 more•Institutions (8)

University College London¹, Newcastle University², University of Plymouth³, Nottingham University Hospitals NHS Trust⁴, John Radcliffe Hospital⁵, University Hospitals Birmingham NHS Foundation Trust⁶, Paris Diderot University⁷, University of Birmingham⁸

01 May 2019-Gastroenterology

TL;DR: In a prospective analysis of patients with NAFLD, FibroScan vibration-controlled transient elastography controlled attenuation parameter (CAP) and liver stiffness measurement (LSMs) found to be effective in assessing liver steatosis and fibrosis, respectively, with AUROC values ranging from 0.70 to 0.89.

...read moreread less

640 citations

Journal Article•DOI•

EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis – 2021 update

[...]

Annalisa Berzigotti, Emmanouil Tsochatzis, Jérôme Boursier, Laurent Castera, Nora Cazzagon, Mireen Friedrich-Rust, Salvatore Petta, Maja Thiele - Show less +4 more

01 Sep 2021-Journal of Hepatology

TL;DR: In this article, the authors provide the latest update to the EASL Clinical Practice Guidelines on the use of non-invasive tests for the evaluation of liver disease severity and prognosis.

...read moreread less

428 citations

Journal Article•DOI•

Liver Ultrasound Elastography: An Update to the World Federation for Ultrasound in Medicine and Biology Guidelines and Recommendations.

[...]

Giovanna Ferraioli¹, Vincent Wai-Sun Wong², Laurent Castera³, Annalisa Berzigotti⁴, Ioan Sporea, Christoph F. Dietrich, Byung Ihn Choi⁵, Stephanie R. Wilson⁶, Masatoshi Kudo⁷, Richard G. Barr⁸ - Show less +6 more•Institutions (8)

University of Pavia¹, The Chinese University of Hong Kong², Paris Diderot University³, University of Bern⁴, Seoul National University Hospital⁵, Foothills Medical Centre⁶, Kindai University⁷, Northeast Ohio Medical University⁸

09 Sep 2018-Ultrasound in Medicine and Biology

TL;DR: This set of guidelines updates the first version, published in 2015, and is aimed at assessing the usefulness of elastography in the management of liver diseases.

...read moreread less

Abstract: The World Federation for Ultrasound in Medicine and Biology has produced these guidelines for the use of elastography techniques in liver diseases. For each available technique, the reproducibility, results and limitations are analyzed, and recommendations are given. This set of guidelines updates the first version, published in 2015. Since the prior guidelines, there have been several advances in technology. The recommendations are based on the international published literature, and the strength of each recommendation is judged according to the Oxford Centre for Evidence-Based Medicine. The document has a clinical perspective and is aimed at assessing the usefulness of elastography in the management of liver diseases.

...read moreread less

319 citations

Journal Article•DOI•

Nonalcoholic fatty liver disease: Evolving paradigms

[...]

Amedeo Lonardo, Fabio Nascimbeni, Mauro Maurantonio, Alessandra Marrazzo, Luca Rinaldi¹, Luigi Elio Adinolfi¹ - Show less +2 more•Institutions (1)

Seconda Università degli Studi di Napoli¹

28 Sep 2017-World Journal of Gastroenterology

TL;DR: NAFLD is highly prevalent in certain cohorts of individuals who are thus potentially amenable to selective screening strategies, intensive follow-up schedules for early identification of liver-related and extrahepatic complications and in whom earlier and more aggressive treatment schedules should be carried out whenever possible.

...read moreread less

Abstract: In the last years new evidence has accumulated on nonalcoholic fatty liver disease (NAFLD) challenging the paradigms that had been holding the scene over the previous 30 years. NAFLD has such an epidemic prevalence as to make it impossible to screen general population looking for NAFLD cases. Conversely, focusing on those cohorts of individuals exposed to the highest risk of NAFLD could be a more rational approach. NAFLD, which can be diagnosed with either non-invasive strategies or through liver biopsy, is a pathogenically complex and clinically heterogeneous disease. The existence of metabolic as opposed to genetic-associated disease, notably including "lean NAFLD" has recently been recognized. Moreover, NAFLD is a systemic condition, featuring metabolic, cardiovascular and (hepatic/extra-hepatic) cancer risk. Among the clinico-laboratory features of NAFLD we discuss hyperuricemia, insulin resistance, atherosclerosis, gallstones, psoriasis and selected endocrine derangements. NAFLD is a precursor of type 2 diabetes (T2D) and metabolic syndrome and progressive liver disease develops in T2D patients in whom the course of disease is worsened by NAFLD. Finally, lifestyle changes and drug treatment options to be implemented in the individual patient are also critically discussed. In conclusion, this review emphasizes the new concepts on clinical and pathogenic heterogeneity of NAFLD, a systemic disorder with a multifactorial pathogenesis and protean clinical manifestations. It is highly prevalent in certain cohorts of individuals who are thus potentially amenable to selective screening strategies, intensive follow-up schedules for early identification of liver-related and extrahepatic complications and in whom earlier and more aggressive treatment schedules should be carried out whenever possible.

...read moreread less

138 citations

1
2
3
4
…
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34

Collapse

References

PDF

Open Access

More filters

Journal Article•DOI•

Design and validation of a histological scoring system for nonalcoholic fatty liver disease

[...]

David E. Kleiner¹, Elizabeth M. Brunt², Mark L. Van Natta³, Cynthia Behling⁴, Melissa J. Contos⁵, Oscar W. Cummings, Linda D. Ferrell⁶, Yao Chang Liu⁷, Michael Torbenson³, Aynur Unalp-Arida³, Matthew M. Yeh⁸, Arthur J. McCullough⁷, Arun J. Sanyal⁹ - Show less +9 more•Institutions (9)

National Institutes of Health¹, Saint Louis University², Johns Hopkins University³, University of California, San Diego⁴, Virginia Commonwealth University⁵, University of California, San Francisco⁶, MetroHealth⁷, University of Washington Medical Center⁸, VCU Medical Center⁹

01 Jun 2005-Hepatology

TL;DR: A strong scoring system and NAS for NAFLD and NASH with reasonable inter‐rater reproducibility that should be useful for studies of both adults and children with any degree ofNAFLD are presented.

...read moreread less

8,253 citations

"Improved Noninvasive prediction of ..." refers background or methods in this paper

...Regarding histology, data from the literature((20)) and from our group((31)) clearly show that overall interobserver agreement for staging severe fibrosis in NAFLD is good; and again different relevant studies assessing FibroScan in histologically defined NAFLD were based on multicenter cohorts....
[...]
...The Kleiner classification((20)) was used to stage fibrosis from 0 to 4....
[...]

Journal Article•DOI•

Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomes

[...]

Zobair M. Younossi¹, Zobair M. Younossi², Aaron B. Koenig¹, Dinan Abdelatif¹, Yousef Fazel¹, Linda Henry, Mark Wymer¹, Mark Wymer² - Show less +4 more•Institutions (2)

Inova Health System¹, Inova Fairfax Hospital²

01 Jul 2016-Hepatology

TL;DR: As the global epidemic of obesity fuels metabolic conditions, the clinical and economic burden of NAFLD will become enormous, and random‐effects models were used to provide point estimates of prevalence, incidence, mortality and incidence rate ratios.

...read moreread less

6,746 citations

"Improved Noninvasive prediction of ..." refers background or methods in this paper

...This picture makes NAFLD as the most common cause of chronic liver disease((1)) as a dramatically growing risk factor for hepatocellular carcinoma,((2)) as a leading indication for liver transplantation,((3)) and as a condition leaving individuals at increased risk of extrahepatic—mostly cardiovascular—morbidity and mortality....
[...]
...Exclusion criteria were as follows: (1) advanced cirrhosis (Child-Turcotte-Pugh B and C); (2) hepatocellular carcinoma; (3) other causes of liver disease or mixed etiologies (alcohol abuse, hepatitis C, hepatitis B, autoimmune liver disease, Wilson disease, hemochromatosis or alpha-1-antitrypsin deficiency); (4) human immunodeficiency virus infection; (5) previous treatment with immunosuppressive drugs and/or regular use of steatosis-inducing drugs, evaluated by a questionnaire (for example, corticosteroid, valproic acid, tamoxifen, amiodarone); or (6) active intravenous drug addiction or use of cannabis....
[...]

Journal Article•DOI•

EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease

[...]

Giulio Marchesini, Christopher P. Day, Jean-François Dufour, Ali Canbay, Valerio Nobili, Vlad Ratziu, Herbert Tilg, Michael Roden, Amalia Gastaldelli, Hannele Yki-Järvinen, Fritz Schick, Roberto Vettor, Gema Frühbeck, Lisbeth Mathus-Vliegen - Show less +10 more

01 May 2016-Journal of Hepatology

TL;DR: The final purpose is to improve patient care and awareness of the importance of NAFLD, and to assist stakeholders in the decision-making process by providing evidence-based data, which also takes into consideration the burden of clinical management for the healthcare system.

...read moreread less

3,117 citations

Journal Article•DOI•

The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD

[...]

Paul Angulo¹, Jason M. Hui², Giulio Marchesini, Ellisabetta Bugianesi³, Jacob George², Geoffrey C. Farrell², Felicity Enders¹, Sushma Saksena⁴, Alastair D. Burt⁴, John P. Bida¹, Keith D. Lindor¹, Schuyler O. Sanderson¹, Marco Lenzi, Leon A. Adams¹, James G. Kench², Terry M. Therneau¹, Christopher P. Day⁴ - Show less +13 more•Institutions (4)

Mayo Clinic¹, University of Sydney², University of Turin³, Freeman Hospital⁴

01 Apr 2007-Hepatology

TL;DR: A simple scoring system accurately separates patients with nonalcoholic fatty liver disease with and without advanced fibrosis, rendering liver biopsy for identification ofAdvanced fibrosis unnecessary in a substantial proportion of patients.

...read moreread less

2,387 citations

Journal Article•DOI•

Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease

[...]

Paul Angulo¹, David E. Kleiner², Sanne Dam-Larsen, Leon A. Adams³, Einar Björnsson⁴, Phunchai Charatcharoenwitthaya⁵, Peter R. Mills⁶, Jill C. Keach⁷, Heather D. Lafferty⁶, Alisha C. Stahler⁷, Svanhildur Haflidadottir⁸, Flemming Bendtsen⁹ - Show less +8 more•Institutions (9)

University of Kentucky¹, National Institutes of Health², University of Western Australia³, University of Iceland⁴, Mahidol University⁵, Gartnavel General Hospital⁶, Mayo Clinic⁷, Oslo University Hospital⁸, Health Science University⁹

01 Aug 2015-Gastroenterology

TL;DR: In a longitudinal study of patients with NAFLD, fibrosis stage, but no other histologic features of steatohepatitis, were associated independently with long-term overall mortality, liver transplantation, and liver-related events.

...read moreread less

2,061 citations

"Improved Noninvasive prediction of ..." refers background or methods in this paper

...Two prospective cohort studies of the natural history of NAFLD patients have clearly shown that the severity of liver fibrosis is the stronger predictor not only of liver-related complications but also of important extrahepatic diseases, including cardiovascular disease and extrahepatic malignancies.((4,5)) Accordingly, the evaluation of liver fibrosis severity has...
[...]
...Exclusion criteria were as follows: (1) advanced cirrhosis (Child-Turcotte-Pugh B and C); (2) hepatocellular carcinoma; (3) other causes of liver disease or mixed etiologies (alcohol abuse, hepatitis C, hepatitis B, autoimmune liver disease, Wilson disease, hemochromatosis or alpha-1-antitrypsin deficiency); (4) human immunodeficiency virus infection; (5) previous treatment with immunosuppressive drugs and/or regular use of steatosis-inducing drugs, evaluated by a questionnaire (for example, corticosteroid, valproic acid, tamoxifen, amiodarone); or (6) active intravenous drug addiction or use of cannabis....
[...]
...This picture makes NAFLD as the most common cause of chronic liver disease((1)) as a dramatically growing risk factor for hepatocellular carcinoma,((2)) as a leading indication for liver transplantation,((3)) and as a condition leaving individuals at increased risk of extrahepatic—mostly cardiovascular—morbidity and mortality.((4,5)) Due to the high prevalence of NAFLD, it is critical to identify those individuals at higher risk of developing both hepatic and extrahepatic complications....
[...]